Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revive Therapeutics Ltd
(CSE:
RVV
)
0.0150
UNCHANGED
Official Closing Price
Updated: 2:41 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Revive Therapeutics Ltd
< Previous
1
2
Next >
Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
February 03, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
January 19, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
January 12, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Ltd. Closes $4.3 Million Offering
January 12, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Publication Showing Bucillamine’s Potential Impact on COVID-19 Omicron Variants
January 09, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
January 05, 2023
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
December 22, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Ltd. Expands Life Offering to Quebec
December 15, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Ltd. Announces Offering of Up to $5 Million
November 30, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
November 24, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
November 22, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
October 14, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
October 06, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
September 28, 2022
From
Revive Therapeutics Ltd.
Via
GlobeNewswire
Why North America Region is Dominating the Billion Dollar Psychedelic Drugs Market
October 05, 2021
Palm Beach, FL – October 5, 2021 – FinancialNewsMedia.com News Commentary – The psychedelic drugs market is creating major potential for treatment of mental illnesses, and as a result, it is likely to...
Via
FinancialNewsMedia
Market For Psychedelic Drugs Expected to Reach $6.9 Billion By 2027
April 14, 2021
Via
FinancialNewsMedia
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.